Short studies leave much unknown
Medicine review is handled by FDA, a US agency.
Its review checked September 28, 2026 found human BPC-157 studies too small and brief, with too little monitoring detail, to establish safety.
FDA's review found no reported serious side effects in those studies. Most did not clearly explain how they checked for harm. This does not show that serious problems cannot happen.
Immune reactions are an unresolved concern
Your immune system provides your body's defences. FDA is concerned it could react to BPC-157 given by injection or through the nose.
Its review says the possible effects of that response can range from unnoticed changes to life-threatening reactions.
This is an assessment of a possible risk, not a measured rate in patients.
A report does not prove the cause
FDA's review described reports after injected BPC-157 of local redness and swelling, breathing trouble and skin or gum darkening.
FDA could not establish that BPC-157 caused the reported problems, and the reports do not tell us how often problems occur.
Severe symptoms need urgent help
US government patient information, checked September 17, 2026, describes severe allergic reactions as emergencies. Signs can include breathing problems or swelling in the tongue or face.
For severe symptoms of an allergic reaction, go to the nearest emergency room.
This is general emergency guidance, not a way to identify a cause yourself.